Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001014839 | SCV001175601 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-09-13 | criteria provided, single submitter | clinical testing | The c.2220_2223dupCAAA pathogenic mutation, located in coding exon 14 of the MSH2 gene, results from a duplication of CAAA at nucleotide position 2220, causing a translational frameshift with a predicted alternate stop codon (p.D742Qfs*9). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV001237914 | SCV001410701 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2024-02-26 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asp742Glnfs*9) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MSH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 820916). For these reasons, this variant has been classified as Pathogenic. |
Myriad Genetics, |
RCV003455089 | SCV004187946 | pathogenic | Lynch syndrome 1 | 2023-08-08 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |